Neogenomics Inc. (NEO)

Schlusskurs vom Vortag:

$13.85

Offen:

$13.91

24-Stunden-Volumen:

798.44K

Marktkapitalisierung:

$1.81B

Einnahmen:

$591.64M

Nettoeinkommen (Verlust:

$-87.97M

KGV:

-18.36

EPS:

-0.77

Netto-Cashflow:

$-30.71M

1W Leistung:

+4.51%

1M Leistung:

-6.73%

6M Leistung:

-2.55%

1J Leistung:

-1.81%

1-Tages-Spanne:

$13.68

$14.35

52-Wochen-Spanne:

$11.03

$21.22

Neogenomics Inc. Stock (NEO) Company Profile

Firmenname

Neogenomics Inc.

Sektor

Healthcare (1191)

Branche

Diagnostics & Research (66)

Telefon

239-768-0600

Adresse

12701 Commonwealth Drive, Suite 9, Fort Myers, FL

Mitarbeiter

1,000

Twitter

@NeoGenomics

Nächster Verdiensttermin

2024-05-23

Neueste SEC-Einreichungen

NEO's Discussions on Twitter

Neogenomics Inc. Stock (NEO) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2023-12-29	Bestätigt	BTIG Research	Buy
2023-08-21	Hochstufung	Stephens	Equal-Weight → Overweight
2023-05-16	Herabstufung	Raymond James	Outperform → Mkt Perform
2023-05-09	Hochstufung	BTIG Research	Neutral → Buy
2023-02-24	Hochstufung	The Benchmark Company	Hold → Buy
2023-02-01	Hochstufung	Needham	Hold → Buy
2022-08-26	Herabstufung	The Benchmark Company	Buy → Hold
2022-08-22	Herabstufung	Needham	Buy → Hold
2022-06-03	Eingeleitet	Piper Sandler	Overweight
2022-03-29	Herabstufung	BofA Securities	Buy → Neutral
2022-03-29	Herabstufung	Stephens	Overweight → Equal-Weight
2022-01-18	Fortgesetzt	Stephens	Overweight
2021-12-16	Eingeleitet	Cowen	Outperform
2021-11-05	Herabstufung	Morgan Stanley	Overweight → Equal-Weight
2021-10-14	Hochstufung	Raymond James	Mkt Perform → Outperform
2021-06-03	Eingeleitet	Goldman	Buy
2021-02-25	Fortgesetzt	Needham	Buy
2021-02-25	Herabstufung	Raymond James	Outperform → Mkt Perform
2021-01-28	Eingeleitet	Truist	Buy
2020-12-11	Fortgesetzt	BTIG Research	Buy
2020-10-28	Bestätigt	Needham	Buy
2020-09-09	Eingeleitet	Morgan Stanley	Overweight
2020-08-28	Eingeleitet	Guggenheim	Buy
2020-07-29	Bestätigt	Needham	Buy
2020-06-25	Eingeleitet	BofA/Merrill	Buy
2020-04-21	Fortgesetzt	Stephens	Overweight
2020-03-02	Fortgesetzt	Craig Hallum	Buy
2020-02-28	Hochstufung	First Analysis Sec	Outperform → Strong Buy
2020-01-23	Herabstufung	First Analysis Sec	Strong Buy → Outperform
2019-10-30	Bestätigt	Needham	Buy
2019-05-01	Bestätigt	Needham	Buy
2019-03-29	Bestätigt	Needham	Buy
2019-01-03	Eingeleitet	Needham	Buy
2018-10-24	Hochstufung	First Analysis Sec	Outperform → Strong Buy
2018-08-21	Eingeleitet	Leerink Partners	Outperform
2018-05-02	Herabstufung	First Analysis Sec	Overweight → Equal-Weight
2017-09-11	Herabstufung	BTIG Research	Buy → Neutral
2017-08-24	Eingeleitet	Gabelli & Co	Buy
2016-12-15	Eingeleitet	Cantor Fitzgerald	Overweight

Alle ansehen

Neogenomics Inc. Aktie (NEO) Neueste Nachrichten

Will Myriad Genetics (MYGN) Report Negative Q1 Earnings? What You Should Know

Zacks Investment Research

NeoGenomics (NEO) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Zacks Investment Research

Absci Corporation (ABSI) Moves 16.8% Higher: Will This Strength Last?

Zacks Investment Research

Wall Street Breakfast: The Week Ahead

Seeking Alpha

All You Need to Know About NeoGenomics (NEO) Rating Upgrade to Buy

Zacks Investment Research

Does NeoGenomics (NEO) Have the Potential to Rally 43.34% as Wall Street Analysts Expect?

Zacks Investment Research

Finanzdaten der Neogenomics Inc.-Aktie (NEO)

Neogenomics Inc. (NEO) Umsatz 2024

Neogenomics Inc. (NEO) Nettogewinn 2024

Neogenomics Inc. (NEO) Free Cashflow 2024

Neogenomics Inc. (NEO) Gewinn je Aktie 2024